Somatostatin inhibits insulin secretion, which can result in elevations in plasma glucose levels; 75% of somatostatinomas located on the pancreatic gland will develop DM, while those in the gastrointestinal tract will only develop DM in 10% of the cases [30]. This evidence concerns the gene INS and diabetes mellitus.